Acute Heart Failure is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Acute Heart Failure have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Acute Heart Failure compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Acute Heart Failure overview

Acute heart failure (AHF) is a critical medical condition characterized by a sudden onset or rapid worsening of symptoms related to the heart’s inability to pump blood effectively. This leads to insufficient oxygen delivery to tissues and organs. AHF can manifest as either new-onset heart failure or exacerbation of chronic heart failure. Common symptoms include shortness of breath, fatigue, and fluid retention, often resulting in pulmonary congestion and peripheral edema. Various factors such as coronary artery disease, hypertension, or infections can precipitate AHF. Prompt diagnosis, often through clinical evaluation and imaging, guides immediate interventions, including medications and, in severe cases, mechanical support or surgical interventions to optimize cardiac function and improve outcomes.

For a complete picture of PTSR and LoA scores for drugs in Acute Heart Failure, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.